Laekna (HKG:2105) narrowed its loss to 229.3 million yuan for the year 2025 from 254.3 million yuan a year prior, according to a Wednesday Hong Kong bourse filing.
The pharmaceutical company's loss per share stood at 0.59 yuan, compared with 0.71 yuan in the previous fiscal year.
The firm recorded a revenue of 106.7 million yuan in the year, whereas no revenue was seen in the previous year.